- 668. Predicting biochemical recurrence and prostate cancer-specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of patients with screening- and clinically detected prostate cancer.
2019
,Journal: BJU International
Reference: doi:10.1111/bju.14790 - 667. Charlson comorbidity index based on hospital episode statistics performs adequately in predicting mortality, but its discriminative ability diminishes over time.
2019
,Journal: Clinical Epidemiology
Reference: 11:923-932. - 666. Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European Randomized study of Screening for Prostate Cancer Risk Calculators
2019
,Journal: Eur Urol
Reference: 2019 Feb;75(2):310-318. - 665. The ERSPC study: quality takes time and perseverance
2019
,Journal: Clin Chem
Reference: 2019 Jan; 65(1):208-209 - 664. Results of prostate cancer screening in a unique cohort at 19yr of follow-up
2019
,Journal: Eur Urol
Reference: 2019 Mar;75(3):374-377 - 663. Could differences in treatment between trial arms explain the reduction in prostate cancer mortality in the European Randomized study of Screening for Prostate cancer?
2019
,Journal: Eur Urol
Reference: 2019 Mar 27. pii: S0302-2838(19)30196-4. doi: 10.1016/j.eururo.2019.03.010. - 662. A 16-year follow-up of the European Randomized study of Screening for Prostate Cancer
2019
,Journal: Eur Urol
Reference: 2019 Feb 26. pii: S0302-2838(19)30150-2. doi: 10.1016/j.eururo.2019.02.009. - 661. Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: analysis of the Finnish randomized study of screening for prostate cancer.
2019
,Journal: Int J Cancer
Reference: 2019 Jan 17. doi:10.1002/ijc.32129 - 660. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.
2019
,Journal: Prostate Cancer Prostatic Dis
Reference: Sep;22(3):483-490. doi:10.1038/s41391-019-0129-2. - 659. Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort.
2018
,Journal: Scand J Urol
Reference: 2018 Oct-Dec;52(5-6):321-327. - 658. The number of screening cycles needed to reduce prostate cancer mortality in the Finnish section of the European Randomized Study of Prostate Cancer (ERSPC).
2019
,Journal: Clin Cancer Res
Reference: 2019 Jan 15;25(2):839-843. doi:10.1158/1078-0432. CCR-18-1807 - 657. Synergistic interaction of HOXB13 and CIP2A predisposes to aggressive prostate cancer.
2018
,Journal: Clin Cancer Res
Reference: 2018 Dec 15;24(24):6265-6276 - 656. Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men.
2018
,Journal: Sci rep
Reference: Jul 9;8(1):10308 - 655. Prostate cancer screening: what can we learn from randomised trials?
2018
,Journal: Transl Androl Urol
Reference: Feb;7(1):12-17 - 654. Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
2018
,Journal: Br J Cancer
Reference: 2018 May;118(9):1248-1254. doi: 10.1038/s41416-018-0055-4. - 653. What is an acceptable false negative rate in the detection of prostate cancer?
2018
,Journal: Transl Androl Urol
Reference: Feb;7(1):54-60 - 652. Screening for prostate cancer: are organized screening programs necessary?
2018
,Journal: Transl Androl Urol
Reference: Feb;7(1):4-11 - 651. Editorial Comment to Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
2018
,Journal: Int J Urol
Reference: Mar;25(3):277 - 650. Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data.
2018
,Journal: Eur J Cancer
Reference: Apr;93:108-118 - 649. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.
2017
,Journal: Prostate Cancer Prostatic Dis
Reference: Dec 22. - 648. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
2017
,Journal: Int J Urol
Reference: Mar;25(3):270-276 - 647. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
2017
,Journal: Eur Urol Focus
Reference: Nov 11. pii: S2405-4569(17)30258-4 - 646. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use
2017
,Journal: J Urol
Reference: Aug;198(2):305-309 - 645. Prostate cancer screening in Europe and Asia.
2017
,Journal: Asian J Urol
Reference: Apr;4(2):86-95 - 644. Summary statement on screening for prostate cancer in Europe.
2018
,Journal: Int J Cancer
Reference: Feb 15;142(4):741-746 - 643. Stopping screening, when and how?
2018
,Journal: Transl Androl Urol
Reference: Feb;7(1):46-53 - 642. Real-time Watchful Surveillance Looks Like Active Waiting.
2017
,Journal: Eur Urol
Reference: Dec;72(6):908-909 - 641. Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.
2017
,Journal: Mod Pathol
Reference: Aug;30(8):1126-1132 - 640. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
2016
,Journal: Eur Urol Focus
Reference: Aug 4. pii: S2405-4569(16)30107-9 - 639. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
2018
,Journal: Scand J Urol
Reference: Feb;52(1):27-37 - 638. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
2018
,Journal: Cancer
Reference: Mar 15;124(6):1197-1206 - 637. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?
2017
,Journal: Eur Urol
Reference: Jun 21. pii: S0302-2838(17)30514-6 - 636. Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
2017
,Journal: BJU Int
Reference: Sep;120(3):394-400 - 635. Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.
2017
,Journal: Int J Urol
Reference: Apr;24(4):281-286 - 634. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
2017
,Journal: Eur Urol
Reference: Jul;72(1):45-51 - 633. Prostate cancer: Draft USPSTF 2017 recommendation on PSA testing – a sea-change?
2017
,Journal: Nat Rev Urol
Reference: Aug;14(8):457-458 - 632. Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.
2017
,Journal: BMC Cancer
Reference: Aug 29;17(1):585 - 631. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
2017
,Journal: Eur Urol Focus
Reference: Aug 10. - 630. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.
2017
,Journal: Ann Intern Med
Reference: Sep 5. - 629. Estimate of opportunistic prostate-specific antigen testing in the Finnish Randomized Study of Screening for Prostate Cancer.
2017
,Journal: J Urol
Reference: Jul;198(1):50-57 - 628. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
2017
,Journal: Int J Cancer
Reference: Jun 15;138(12):2820-8 - 627. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
2017
,Journal: Scand J Urol
Reference: Jan 13:1-11 - 626. Reply from Authors re: Roderick C.N. van den Bergh, Declan G. Murphy, Henk G. van der Poel. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. Eur Urol 2016;70:767-8.
2016
,Journal: Eur Urol
Reference: Nov;70(5):769-770 - 625. Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial.
2016
,Journal: J Med Screen
Reference: Aug 9. - 624. Corrigendum re: “Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial” [Eur Urol 2016;70:566-73].
2016
,Journal: Eur Urol
Reference: Feb;71(2):e81 - 623. Impact of cause of death adjudication on the results of the European prostate cancer screening trial.
2017
,Journal: Br J Cancer
Reference: Jan 3;116(1):141-148 - 622. What explains the differences between centres in the European screening trial? A simulation study.
2016
,Journal: Cancer Epidemiol
Reference: Nov 24;46:14-19 - 621. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.
2016
,Journal: Cancer
Reference: Nov 15;122(21):3386-3393 - 620. Correction: Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
2016
,Journal: Clin Cancer Res
Reference: Jul 15;22(14):3702 - 619. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
2016
,Journal: Eur Urol Focus
Reference: June 2.